Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Walgreens (WBA) reports sales growth and strategic initiatives progress

Walgreens (WBA) Q1 2025 earnings call highlighted sales growth, progress in pharmacy operations, and challenges in consumer retail business. The company is focusing on stabilizing its U.S. Retail Pharmacy business, improving operational efficiency, and driving long-term value creation. Opportunities exist in cost savings initiatives, strategic turnaround efforts, and sustained positive cash flow generation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life science.

Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 18, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) common stock between July 1, 2021 and June 26, 2024, inclusive (the “Class Period”). If you suffered a loss on your Walgreens investments or would like to inquire about potent.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Walgreens Boots Alliance, Inc. (WBA)

In addition to weak consumer behavior and retail pharmacy industry headwinds, app downloads data suggests Walgreens is lagging vs. competition such as CVS. WBA has missed on margin expectations for multiple quarters now, and these pressures are expected to continue due to a tough pricing environment. Despite trough discount valuations vs. comps, WBA stock is in a value trap as the stock falls primarily due to earnings downgrades in the absence of catalysts.

Walgreens: No Catalysts To Drive A Turnaround

Kraft Heinz

Philip Morris

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 18, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) common stock between July 1, 2021 and June 26, 2024, inclusive (the “Class Period”). Investors suffering losses on their Walgreens investments are encouraged to contact the Law Offices of Howard G. Smith to discu.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Walgreens Boots Alliance, Inc. (WBA)

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens, the leading independent retail pharmacy and healthcare provider, is announcing today the launch of the Walgreens Student Loan 401(k) Match Program. This new benefit, available beginning in January 2025, will allow team members to qualify for company 401(k) match contributions as they pay down their student loans. “We understand the burden student loan debt places on many of our team members, and this program empowers us to make a lasting impact on th.

Walgreens Announces New Student Loan 401(k) Match Program

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) common stock between July 1, 2021 and June 26, 2024, inclusive (the “Class Period”). Walgreens investors have until November 18, 2024 to file a lead plaintiff motion. If you suffered a loss on.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Walgreens Boots Alliance, Inc. (WBA) Investors

Magna International

U.S. Bancorp

September 30, 2024 (Maple Hill Syndicate) – Geraldine Weiss, who died two years ago at age 96, was a successful investment newsletter writer at a time when few women were prominent in finance. She wrote a book called Dividends Don't Lie.

Dividends Don't (Usually) Lie

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Walgreens Boots Alliance, Inc. (WBA) Investors.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Walgreens Boots Alliance, Inc. (WBA) Investors

Walgreens (WBA) faces a challenging outlook with weak profit forecasts and negative EPS revisions, but technical signals suggest a potential upside, prompting a buy rating. Despite bearish trends and a recent dividend cut, WBA's valuation metrics are extremely low, making it a high-risk, potentially undervalued investment. Key risks include a shift away from physical stores and commercial real estate weakness, but WBA's free cash flow remains positive, mitigating immediate cash-burn concerns.

Walgreens: So Bad It's Good Heading Into Earnings (Rating Upgrade)

Walgreens Boots Alliance (WBA) has become a fallen angel, costing investors billions of dollars in the past few years. Its stock has imploded, falling from $69 in 2014 to $9 today, meaning that a $1000 investment at its top would now be worth just $130.

Walgreens stock is cheap and oversold: is it a value trap?

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) common stock between July 1, 2021 and June 26, 2024, inclusive (the “Class Period”). Walgreens investors have until November 18, 2024 to file a lead plaintiff motion. Investors suffering losses on their Walgreens investments are encouraged to contact the Law Offices of.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Walgreens Boots Alliance, Inc. (WBA) Investors

Walgreens stock is taking a hit, in part, because of prescription reimbursement pressures from insurers. Walgreens also made a poor acquisition that continues to weigh on its results.

5 Things You Need to Know If You Buy Walgreens Today

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Walgreens investments or would like to inquire about potentially pursuing claims to recover your loss under the federa.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Walgreens Boots Alliance, Inc. (WBA) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) investors concerning the Company's possible violations of federal securities laws. On June 27, 2023, Walgreens released its third quarter fiscal 2023 financial results, falling below analysts' expectations. Additionally, the Company lowered its fiscal 2023 guidance due to “a slower profit ramp for U.S. health care” rel.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Walgreens Boots Alliance, Inc. (WBA) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On June 27, 2023, Walgreens released its third quarter fiscal 2023 financial results, falling below analysts' expectations. Additionally, the Company lowered its.

The Law Offices of Frank R. Cruz Announces Investigation of Walgreens Boots Alliance, Inc. (WBA) on Behalf of Investors

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Walgreens Boots Alliance presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Walgreens Boots Alliance Is Oversold

High dividend yields can trick investors into buying low-quality or distressed stocks. Walgreens faces several challenges that have deteriorated its fundamentals.

Should You Buy Walgreens Boots Alliance for Its 11.1% Dividend Yield? 3 Things to Know First

In the most recent trading session, Walgreens Boots Alliance (WBA) closed at $8.53, indicating a -0.35% shift from the previous trading day.

Walgreens Boots Alliance (WBA) Stock Drops Despite Market Gains: Important Facts to Note

WBA is currently facing challenges within its U.S. Retail Pharmacy segment due to an unfavorable consumer environment and adverse pharmacy industry trends.

WBA Stock Dips 5% Post Fed Rate Cut: Should You Sell Walgreens Boots?

Walgreens is struggling and is considering closing stores and selling assets. It brought on a new CEO last year who appears to be considering a wide range of possible moves for the business.

3 Reasons Why Walgreens Boots Alliance Stock May Not Be Doomed

SAN DIEGO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of purchasers of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) (“Walgreens” or the “Company”) common stock between July 1, 2021 and June 26, 2024, inclusive (the “Class Period”), charging the Company and certain of its current and former senior executives with violations of the federal securities laws (collectively, “Defendants”).

INVESTOR ALERT: DiCello Levitt LLP Shareholder Class Action Lawsuit Filed Against Walgreens Boots Alliance, Inc. (NASDAQ: WBA); Investors with Losses Encouraged to Discuss Their Options with Counsel

In the most recent trading session, Walgreens Boots Alliance (WBA) closed at $9.01, indicating a -0.55% shift from the previous trading day.

Walgreens Boots Alliance (WBA) Suffers a Larger Drop Than the General Market: Key Insights

BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Saxena White P.A. has filed a securities fraud class action lawsuit (the “Class Action”) in the United States District Court for the Northern District of Illinois against Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) and certain of its executive officers (collectively, “Defendants”). The Class Action asserts claims under Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 (the “Exchange Act”) and U.S. Securities and Exchange Commission (“SEC”) Rule 10b-5 promulgated thereunder on behalf of all persons or entities who purchased Walgreens common stock between July 1, 2021 and June 26, 2024, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Saxena White is captioned: Westchester Putnam Counties Heavy & Highway Laborers Local 60 Benefits Fund v. Walgreens Boots Alliance, Inc., et al., No. 24-cv-8559 (N.D. Ill.).

Saxena White P.A. Files New Securities Fraud Class Action Lawsuit Against Walgreens Boots Alliance, Inc. and Certain of Its Executives

SAN DIEGO--(BUSINESS WIRE)--Uqora, the rapidly growing and cutting-edge urinary tract health brand, today announces its retail expansion into 7,600 Walgreens stores nationwide and online at Walgreens.com. Through its growing omnichannel presence, the digitally native brand continues to revolutionize the urinary care aisle with its innovative line of proactive urinary tract health supplements and UTI symptom relief products. “By continuing to expand into retail, Uqora is meeting consumers where.

News for Walgreens Stock (WBA)